Indolent Non-Hodgkin’s Lymphoma
Conditions
Interventions
Test Group:Thalidomide and Interferon
control:Thalidomide and Interferon
Sponsors
The Affiliated Cancer Hospital of Zhengzhou University/Henan Cancer Hospital
Eligibility
Sex/Gender
Male
Age
18 Years to 80 Years
Inclusion criteria
Inclusion criteria: (1) 18 to 80 years of age; (2)male and female; (3)diagnosed indolent non-Hodgkin's lymphoma; (4)not exposed to chemotherapy?radiotherapy and other antineoplastons within 1 month; (5)cardiac function NYHA class45%,antharcyclines cumulative dose less than 240mg/m2(6)STB=1.5×institutional upper limit of normal (ULN),ALT,AST=2.5×ULN; (7) BUN,SCr?2.5×ULN; (8) without other malignancy,or severe infection; (9) ECOG performance status ?2; (10) expected survival time>3 months; (11) signed informed consent.
Exclusion criteria
Exclusion criteria: (1) not diagnosed indolent non-Hodgkin's lymphoma; (2)serious allergy to thalidomide or interferon with clinical manifestation of anaphylactic shock and laryngeal edema; (3) in the course of chemotherapy,radiotherapy and other antineoplastons; (4) suffered with malignancy in addition to NHL,severe infection or central nervous system NHL; (5) have significant heart disease activity within the previous 6 months:MI,class ?-? congestive heart failure according to NYHA,unstable ungina,unstable pericardiac disease and cardiac amyloidosis; (6) ?2 peripheral neuropathy according to NCTCTCAE 4.0; (7) ALT,AST?2.5×ULN,STB?1.5×ULN; (8) pregnancy or nursing; (9) lung function decompensation; (10) renal failure; (11) psychotic episodes.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Overall response rate;complete remission;part remissio; | — |
Secondary
| Measure | Time frame |
|---|---|
| Duration of response;Progress-free surviva; | — |
Countries
China
Contacts
Public ContactWei Xudong
Outcome results
None listed